Anti-MUC1 and anti-EGFR (cetuximab) antibodies have achieved effective antitumor effects in carcinoma A549 cancer cells, causing tumor regression by inhibiting the binding of SIRPα and CD47 [106] (Figure 4). Here, SIRPA is linked to neoplasm.